A phase 2 study of a brachyury‐targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma
Cancer · 2024
DOI: 10.1002/cncr.35477 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer, 2024. Verfasst von Gregory M Cote und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mass General Cancer Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Chordoma, Fetal Proteins, T-Box Domain Proteins, Cancer Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Bavarian Nordic.
Abstract (Originalsprache)
Background
This was a single‐arm, phase 2 clinical trial of Bavarian Nordic (BN)‐Brachyury vaccine plus radiotherapy (RT) designed to determine the objective response rate (ORR), progression‐free survival (PFS), and safety of the combination in chordoma.
Methods
A total of 29 adult patients with advanced chordoma were treated with two subcutaneous priming vaccine doses of modified vaccinia Ankara‐Bavarian Nordic (MVA‐BN)‐Brachyury and one vaccine dose of fowlpox virus (FPV)‐Brachyury before RT. After RT, booster vaccinations were given with FPV‐Brachyury every 4 weeks for 4 doses, then every 12 weeks (week 110). A minimum RT dose of >8 Gy in one fraction for each target was required. Response was evaluated by modified Response Evaluation Criteria in Solid Tumors 1.1 (mRECIST), where only radiated lesions were considered targets, and by standard RECIST 1.1 in a subset of patients.
Results
Two of 26 evaluable patients experienced durable partial response (PR) (ORR of 7.7%; 90% confidence interval [CI], 2.6–20.8]) by mRECIST 1.1. A total of 21 patients (80.8%; 90% CI, 65.4–90.3) had stable disease, and three patients (11.5%; 90% CI, 4.7–25.6) had progressive disease as best response per mRECIST 1.1. Median PFS was not reached during the study.
Conclusions
This trial confirms the safety of BN‐Brachyury and RT. Although the study did not meet the predefined study goal of four responses in 29 patients, we did observe two PRs and a PFS of greater than 2 years. For a vaccine‐based study in chordoma, an ultra‐rare disease where response rates are low, a randomized study or novel trial designs may be required to confirm activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mass General Cancer Center, Boston, Massachusetts, USA.
- The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Mayo Clinic in Florida, Jacksonville, Florida, USA.
- Washington University School of Medicine, St. Louis, Missouri, USA.
- Mayo Clinic in Arizona, Phoenix, Arizona, USA.
- BNC Affiliation, Bavarian Nordic Inc, Durham, North Carolina, USA.
ORCID-Profile: Brian A Van Tine
Förderung
- Bavarian Nordic
Zitieren
APA
Cote, G. M., Conley, A. P., Attia, S., Van Tine, B. A., Seetharam, M., Chen, Y. L., Gafoor, Z., Heery, C., Pico-Navarro, C., & Adams, T. (2024). A phase 2 study of a brachyury‐targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma. Cancer. https://doi.org/10.1002/cncr.35477
Vancouver
Cote GM, Conley AP, Attia S, Van Tine BA, Seetharam M, Chen YL, et al. A phase 2 study of a brachyury‐targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma. Cancer. 2024. doi:10.1002/cncr.35477
BibTeX
@article{Cote2024,
author = {Cote, Gregory M and Conley, Anthony P and Attia, Steven and Van Tine, Brian A and Seetharam, Mahesh and Chen, Yen-Lin and Gafoor, Zarina and Heery, Christopher and Pico-Navarro, Cesar and Adams, Tatiana},
title = {A phase 2 study of a brachyury‐targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35477}
}
EUVIMED